7-Hydroxymitragynine (7-OH): Regulatory Developments and Clinical Considerations
FDA recommendation for Schedule I classification and state-level regulatory responses
In July 2025, the U.S. Food and Drug Administration (FDA) formally recommended that the Drug Enforcement Administration (DEA) classify 7-hydroxymitragynine (7-OH) as a Schedule I controlled substance [1]. This recommendation reflects federal concerns about synthetic and concentrated forms of this compound, which are chemically distinct from traditional kratom leaf products.
Key Points
- Federal Recommendation: FDA has recommended DEA classify 7-OH as Schedule I [1]
- State Actions: Florida classified 7-OH as Schedule I in August 2025 [2]; New York legislation is under review
- Local Regulations: Suffolk County, NY restricts sales to individuals 21 and older (Local Law No. 37-2016) [3]
- Clinical Concerns: Limited evidence exists on long-term effects; reports of dependence and withdrawal have been documented [4]
- Product Distinction: Synthetic/concentrated 7-OH differs significantly from traditional kratom leaf
What is 7-Hydroxymitragynine?
7-hydroxymitragynine (7-OH) is an alkaloid compound that acts as a mu-opioid receptor agonist [5]. It occurs naturally in trace amounts—typically less than 2% of total alkaloid content—in the leaves of Mitragyna speciosa, commonly known as kratom [6]. Recent regulatory attention has focused on products containing synthetic or highly concentrated forms of 7-OH, which differ substantially from traditional kratom preparations.
The Critical Distinction
Natural Kratom
- • Contains <2% 7-OH alkaloids
- • Balanced alkaloid profile
- • Traditional herbal use
- • Not targeted by FDA recommendation
Synthetic/Concentrated 7-OH
- • Up to 13x more potent than morphine
- • Isolated or synthesized compound
- • Marketed as "enhanced kratom"
- • Subject of FDA Schedule I recommendation
Reports from poison control centers and healthcare providers have documented cases of dependence and withdrawal associated with concentrated 7-OH products [7]. Clinical presentations have included symptoms consistent with opioid withdrawal, though the full scope of effects remains under study. More research is needed to fully characterize the pharmacology and long-term health impacts of these products.
Federal Classification Efforts
FDA's July 2025 Recommendation
On July 29, 2025, the FDA issued a recommendation to the DEA proposing Schedule I classification for 7-hydroxymitragynine [1]. The agency's decision was based on:
- Pharmacological analysis of 7-OH's opioid receptor activity
- Review of adverse event data from poison control centers and healthcare facilities
- Assessment of abuse potential and lack of FDA-approved medical use
- Input from stakeholders including consumer advocacy groups and industry representatives
FDA Statement (July 29, 2025)
"This recommendation follows a thorough medical and scientific analysis by the FDA and is one of several efforts to address the agency's concerns around dangerous products that contain or are disguised or marketed as kratom."
Source: FDA Press Release
What Schedule I Classification Means
If the DEA accepts the FDA's recommendation, 7-OH would be classified alongside:
Heroin
Diacetylmorphine
LSD
Lysergic acid diethylamide
MDMA
Ecstasy/Molly
State and Local Legislation
Florida's State-Level Classification (August 2025)
On August 13, 2025, Florida implemented an emergency rule classifying 7-hydroxymitragynine as a Schedule I controlled substance under state law [2]. This action:
- Prohibited the sale and distribution of 7-OH products in Florida
- Established criminal penalties for violations consistent with other Schedule I substances
- Represented the first state-level emergency classification of 7-OH
- May inform regulatory approaches in other jurisdictions
Florida AG Statement
"We are immediately removing dangerous 7-OH from store shelves to protect Florida families from this synthetic opioid threat."
Attorney General James Uthmeier, August 13, 2025
New York State Legislation
Senate Bill S7379 (2025) proposes adding kratom and its primary active alkaloids—including concentrated 7-OH—to New York's list of Schedule I controlled substances. Key provisions include:
- Schedule I classification for synthetic and concentrated 7-OH products
- Mandatory warning labels on kratom-containing products
- Ban on misleading "all natural" claims for products with added 7-OH
- Minimum purchase age of 21 for kratom products
Suffolk County Local Law (Already in Effect)
Local Law No. 37-2016 already prohibits the sale or distribution of kratom products—including 7-OH derivatives—to individuals under the age of 21 in Suffolk County, New York. This law has been in effect since 2016 and includes:
- Age verification requirements for retailers
- Civil and criminal penalties for violations
- Authority for local law enforcement to confiscate non-compliant products
Other New York Counties with Kratom Restrictions
Suffolk County
Age 21+ requirement since 2016
Nassau County
Currently under review
Health Risks of 7-OH Products
Reported Health Concerns
Acute Effects
- • Respiratory depression [8]
- • Sedation and drowsiness
- • Potential interactions with central nervous system depressants
- • Nausea and vomiting
- • Cognitive impairment
Long-term Considerations
- • Physical dependence with regular use [9]
- • Withdrawal symptoms upon discontinuation
- • Tolerance development requiring increased doses
- • Limited data on long-term health outcomes
- • Uncertain safety profile with prolonged use
Note on Evidence: Most clinical data on 7-OH effects comes from case reports and poison control center data rather than controlled clinical trials [10]. Further research is needed to fully characterize health risks and establish evidence-based treatment protocols.
Clinical Reports and Surveillance Data
Healthcare providers and poison control centers have documented increasing reports of adverse events associated with concentrated 7-OH products [7]:
Reported Case Trends
- • Withdrawal presentations consistent with opioid agonist cessation
- • Reports of dependence developing with regular use
- • Emergency department visits involving 7-OH products have increased
- • Many users report being unaware of product composition and potency
Source: Surveillance data from regional poison control centers, 2023-2025 [11]
Poison Control Surveillance
National poison control data shows increased exposure reports for products labeled as containing 7-OH [12]:
- 2023: Baseline reporting period
- 2024: Notable increase in exposure reports
- 2025: Continued upward trend through August
Data Limitations: Exposure reports reflect calls to poison control centers and may not capture all adverse events. Underreporting is common in substance use surveillance systems.
Considerations for Long Island Residents
Several factors relevant to Long Island residents include:
- Product availability: 7-OH-containing products have been sold in retail locations including smoke shops and convenience stores
- Labeling concerns: Products may be marketed as "herbal supplements" without clear disclosure of synthetic content
- Regulatory status: Suffolk County has age restrictions; state-level regulations under consideration
- Information access: Public awareness of product composition and potential risks remains limited
Support Resources in Nassau & Suffolk Counties
If you are concerned about substance use involving 7-OH or other compounds, clinical support is available:
Medical Assessment Programs
Healthcare providers can assess symptoms and provide clinical guidance
→ View assessment optionsRegulatory Timeline and Outlook
Q4 2025
DEA review of FDA recommendation; potential public comment period
Q1 2026
Possible implementation of federal classification if approved
New York State Legislation
Senate Bill S7379 under review; implementation timeline uncertain
Disclaimer
This article provides general information based on publicly available sources including FDA recommendations, state legislation, and published research current as of November 2025. It does not constitute medical advice. Drug classifications and legal statuses may change. Individuals seeking health guidance should consult qualified healthcare providers. For medical emergencies, call 911.
Medical Review: This article was reviewed by Brandon McNally, RN, ICU Critical Care Nurse. Last reviewed: November 26, 2025.
References
- U.S. Food and Drug Administration. (2025, July 29). FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers.https://www.fda.gov
- Florida Office of the Attorney General. (2025, August 13). Attorney General Files Emergency Rule Regarding 7-Hydroxymitragynine. Press release.
- Suffolk County, New York. (2016). Local Law No. 37-2016: Prohibiting the sale of kratom to persons under twenty-one years of age.
- International Society of Substance Use Professionals. (2025). Substance Use Surveillance Report.https://www.issup.net
- Váradi, A., et al. (2016). Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism. Journal of Medicinal Chemistry, 59(18), 8381-8397.
- Prozialeck, W. C., et al. (2012). Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. Journal of the American Osteopathic Association, 112(12), 792-799.
- American Association of Poison Control Centers. (2025). National Poison Data System Annual Report.
- Eastlack, S. C., et al. (2020). Kratom—Pharmacology, clinical implications, and outlook: A comprehensive review. Pain Physician, 23, 145-168.
- Coe, M. A., et al. (2019). Kratom as a substitute for opioids: Results from an online survey. Drug and Alcohol Dependence, 202, 24-32.
- Henningfield, J. E., et al. (2018). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 183, 134-140.
- Regional Poison Control Centers. (2023-2025). Surveillance Data on Kratom and 7-OH Exposures. Unpublished data.
- National Poison Data System. (2025). Trends in Kratom and Novel Alkaloid Exposures. Annual surveillance report.
Note on Sources: This article synthesizes information from government regulatory agencies, peer-reviewed scientific literature, and public health surveillance systems. Where clinical evidence is limited or emerging, this has been noted in the text. References reflect sources available as of November 2025.
Related Articles & Resources
Opioid Use Disorders
Information on opioid pharmacology, clinical effects, and treatment approaches.
Clinical Assessment Services
Information on medical assessment and withdrawal management programs.
Nassau County Treatment Resources
Find addiction treatment centers and support services in Nassau County.
Suffolk County Treatment Resources
Comprehensive guide to addiction services in Suffolk County, NY.
Frequently Asked Questions
Get answers to common questions about our 24/7 crisis helpline and addiction support services.
Still have questions? Our crisis counselors are available 24/7.
Call 631-762-3763